Abstract
In this issue of Blood, Byrd et al report that after nearly 4 years of follow-up, there is an impressive and sustained progression-free survival and overall survival benefit to using the Bruton's tyrosine kinase inhibitor ibrutinib vs ofatumumab in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). Nevertheless, patients with specific high-risk features like TP53 or SF3B1 mutations showed a trend toward shorter progression-free survival, and altogether, only half of the enrolled patients were still receiving ibrutinib at the end of the observation period. 1
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| Fakultät: | Medizin |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| ISSN: | 0006-4971 |
| Sprache: | Englisch |
| Dokumenten ID: | 79961 |
| Datum der Veröffentlichung auf Open Access LMU: | 15. Dez. 2021, 14:50 |
| Letzte Änderungen: | 15. Dez. 2021, 14:50 |
- Dokument bearbeiten
